Ontology highlight
ABSTRACT:
SUBMITTER: Rodrik-Outmezguine VS
PROVIDER: S-EPMC4902179 | biostudies-literature | 2016 Jun
REPOSITORIES: biostudies-literature
Rodrik-Outmezguine Vanessa S VS Rodrik-Outmezguine Vanessa S VS Okaniwa Masanori M Yao Zhan Z Novotny Chris J CJ McWhirter Claire C Banaji Arpitha A Won Helen H Wong Wai W Berger Mike M de Stanchina Elisa E Barratt Derek G DG Cosulich Sabina S Klinowska Teresa T Rosen Neal N Shokat Kevan M KM
Nature 20160518 7606
Precision medicines exert selective pressure on tumour cells that leads to the preferential growth of resistant subpopulations, necessitating the development of next-generation therapies to treat the evolving cancer. The PIK3CA-AKT-mTOR pathway is one of the most commonly activated pathways in human cancers, which has led to the development of small-molecule inhibitors that target various nodes in the pathway. Among these agents, first-generation mTOR inhibitors (rapalogs) have caused responses ...[more]